Skip to main content
Multiple Sclerosis Discovery Forum
Inspiring Connections
Utility Navigation
Feedback
Newsletter
RSS
Twitter
User Top Menu
Welcome, guest
Log In
Join
Why Join?
Search form
Search
About Us
Overview
Who We Are
Contact
Fan Mail
How to Cite
News & Future Directions
New Findings
News Briefs
Podcasts
News Synthesis
Essays & Opinions
Blogs
Papers
Editors' Picks
Classic Papers
Archive
Forums
Discussions
Webinars
Professional Resources
Meetings & Events
Past Meetings
Funding Opportunities
Jobs
Member Directory
Bulletin Board
Useful Links
Research Resources
Data Visualizations
Clinical Trials - Public Availability of Results
World Map
MS trials baseline
NMO History
NMO Galaxy
Map of MS Prevalence
Progressive MS Authors Galaxy
Word Cloud
MSLine
Ongoing Clinical Trials in MS
MRI-Related Clinical Trials
RRMS and CIS
Immunopathogenesis of MS
The MS Galaxy
ARR in Placebo Groups
Symptoms Prevalence
Scientific Literature TreeMap
Clinical Trials in MS
Drug-Development Pipeline
Tissue Repositories
MSGene
Animal Models
Clinical Trials
Click Here to Support MSDF
You are here
Home
Most Viewed Papers
Can meditation influence quality of life, depression, and disease outcome in multiple sclerosis? Findings from a large international web-based study.
Glutathione PEGylated liposomal methylprednisolone (2B3-201) attenuates CNS inflammation and degeneration in murine myelin oligodendrocyte glycoprotein induced experimental autoimmune encephalomyelitis.
[Demyelinating process in systematic rheumatoid diseases (review)].
Established and novel disease-modifying treatments in multiple sclerosis.
The Influence of T Cell Ig Mucin-3 Signaling on Central Nervous System Autoimmune Disease Is Determined by the Effector Function of the Pathogenic T Cells.
Low 25-hydroxyvitamin D, but not the bioavailable fraction of 25-hydroxyvitamin D, is a risk factor for multiple sclerosis.
The Wnt Effector Transcription Factor 7-Like 2 Positively Regulates Oligodendrocyte Differentiation in a Manner Independent of Wnt/β-Catenin Signaling.
Mycophenolate mofetil in combination with interferon beta-1a in the treatment of relapsing-remitting multiple sclerosis: A preliminary study.
Measuring the Impact of Secondary Progressive Multiple Sclerosis (Spms) in the Ascend Trial: Equating the Msis-29, Msws-12, Abilhand-56 and Sf-36.
The Importance of Nitric Oxide and Arginase in the Pathogenesis of Acute Neuroinflammation: Are Those Contra Players with the Same Direction?
Increasing consistency of disease biomarker prediction across datasets.
Diagnostic modalities in multiple sclerosis: Perspectives in children.
The Effects of Threonine Phosphorylation on the Stability and Dynamics of the Central Molecular Switch Region of 18.5-kDa Myelin Basic Protein.
Tryptophan Metabolites and Their Impact on Multiple Sclerosis Progression.
Mining gene expression data of multiple sclerosis.
Central adaptation after optic neuritis: Is the whole greater than the sum of its parts?
T cell-activation in neuromyelitis optica lesions plays a role in their formation.
Loss of branched o-mannosyl glycans in astrocytes accelerates remyelination.
"Response to the Commentary on "Neuromyelitis Optica: Potential Roles for Intravenous Immunoglobulin"
Mean upper cervical cord area (MUCCA) measurement in long-standing multiple sclerosis: Relation to brain findings and clinical disability.
Optic neuritis as an initial manifestation of human herpesvirus 6 reactivation after unrelated bone marrow transplantation.
Seeking balance: Potentiation and inhibition of multiple sclerosis autoimmune responses by IL-6 and IL-10.
Estimation of the multiple sclerosis risk in population living on contaminated territories after the Chornobyl catastrophe.
Quality of life in patients with multiple sclerosis in Republic of Srpska.
Intravenous immunoglobulin for chronic inflammatory demyelinating polyradiculoneuropathy.
Pages
« first
‹ previous
…
493
494
495
496
497
498
499
500
501
…
next ›
last »